Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 314 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Anticoagulation Therapy Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin

NCT02206087
View directory record Official record
Conditions
Healthy
Interventions
PER977, Placebo, Heparin Sodium
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 26, 2026, 5:47 PM EDT
Not listed Phase 4 Interventional

Rapid Atrial Fibrillation Treatment Strategy

NCT04092621
View directory record Official record
Conditions
New Onset Atrial Fibrillation, Sepsis, Respiratory Failure
Interventions
Amiodarone in Parenteral Dosage Form, Amiodarone Pill, Direct Current Cardioversion (DCC), Rate-control therapy
Drug · Procedure
Lead sponsor
Our Lady of the Lake Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Safety and Dose Finding Study of Xigris in Hemodialysis Patients

NCT01227187
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Drotrecogin alfa activated (Xigris)
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 2 Interventional

Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI

NCT00715455
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
REG1, Unfractionated Heparin
Drug
Lead sponsor
Regado Biosciences, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Indianapolis, Indiana • Detroit, Michigan • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Improving the Quality of Care for Atrial Fibrillation by Promoting Patient-Centered Decision Making

NCT00829478
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Decision Aid for Atrial Fibrillation, Usual Care
Behavioral · Other
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
45 Years and older
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Not applicable Interventional Results available

Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation

NCT03795298
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
WATCHMAN FLX Implant, Market-approved OAC
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 26, 2026, 5:47 PM EDT
Active, not recruiting Phase 3 Interventional

Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy

NCT05591118
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Anticoagulant Therapy, Catheter-Directed Therapy
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
40
States / cities
Birmingham, Alabama • Palo Alto, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 26, 2026, 5:47 PM EDT
Terminated Phase 3 Interventional

Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial

NCT02448550
View directory record Official record
Conditions
Percutaneous Coronary Intervention
Interventions
Bivalirudin, Unfractionated heparin
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 26, 2026, 5:47 PM EDT
Not listed Phase 2 Interventional

Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19

NCT04377997
View directory record Official record
Conditions
Cardiovascular Diseases, COVID-19
Interventions
Enoxaparin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 26, 2026, 5:47 PM EDT
Completed No phase listed Observational

Evaluation of Maternal and Fetal Outcomes in Pregnancies in Women With Prosthetic Heart Valves

NCT00329290
View directory record Official record
Conditions
Pregnancy, Anticoagulation, Prosthetic Heart Valves
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Early Phase 1 Interventional

Study Using Citrate to Replace Heparin in Babies Requiring Extracorporeal Membrane Oxygenation (ECMO)

NCT00968565
View directory record Official record
Conditions
Heart Defects, Congenital, Respiratory Insufficiency
Interventions
sodium citrate
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
1 Day to 1 Year
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 26, 2026, 5:47 PM EDT
Terminated Phase 4 Interventional Results available

A Comparison of Dilute Versus Concentrated Heparin for CRRT Anticoagulation

NCT01318811
View directory record Official record
Conditions
Acute Kidney Injury, Acute Renal Failure, Heart Failure
Interventions
Dilute unfractionated heparin, Standard concentration unfractionated heparin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Not applicable Interventional Results available

Role of a Novel Exercise Program to Prevent Post-thrombotic Syndrome

NCT02148029
View directory record Official record
Conditions
Acute Deep Vein Thrombosis
Interventions
Exercise, Standard Care
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)

NCT02329327
View directory record Official record
Conditions
Bleeding
Interventions
Andexanet
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 26, 2026, 5:47 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

NCT04755283
View directory record Official record
Conditions
Atrial Fibrillation (AF), Stroke
Interventions
Abelacimab, Rivaroxaban
Biological · Drug
Lead sponsor
Anthos Therapeutics, Inc.
Industry
Eligibility
55 Years and older
Enrollment
1,287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
28
States / cities
Huntsville, Alabama • Mobile, Alabama • Stamford, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 26, 2026, 5:47 PM EDT
Not listed Phase 4 Interventional

Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation

NCT03965208
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation Complication, Anticoagulants
Interventions
Bivalirudin, Unfractionated heparin
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Not applicable Interventional

Using a Real-Time Risk Prediction Model to Predict Pediatric Venous Thromboembolism (VTE) Events

NCT04574895
View directory record Official record
Conditions
Venous Thromboembolism, Pediatrics, Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Hematology Review
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
0 Years to 21 Years
Enrollment
17,427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study

NCT01747746
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Thrombo-embolism, Bleeding
Interventions
Rivaroxaban, Warfarin and Enoxaparin
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

NCT00433966
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Bivalirudin, Unfractionated heparin, Bare metal stent, Paclitaxel-eluting stent
Drug · Device
Lead sponsor
Cardiovascular Research Foundation, New York
Other
Eligibility
18 Years and older
Enrollment
3,602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 26, 2026, 5:47 PM EDT
Completed No phase listed Observational

Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data

NCT04818151
View directory record Official record
Conditions
Venous Thromboembolic Disease, Kidney Failure, Chronic
Interventions
Warfarin, Apixaban
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
14,914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Oct 26, 2026, 5:47 PM EDT
Terminated Phase 2 Interventional Results available

Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease

NCT01036802
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Warfarin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 26, 2026, 5:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Relationship Between Osteoporosis and Chronic Oral Anticoagulation Therapy With Warfarin

NCT00665613
View directory record Official record
Conditions
Osteoporosis
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 26, 2026, 5:47 PM EDT
Withdrawn No phase listed Observational

Dabigatran Versus Warfarin Anticoagulation Before and After Catheter Ablation for the Treatment of Atrial Fibrillation

NCT01607359
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 1 Interventional

Safety and Dosing Evaluation of REG1 Anticoagulation System

NCT00113997
View directory record Official record
Conditions
Healthy
Interventions
REG1
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 26, 2026, 5:47 PM EDT